(Q37799251)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20935674%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

title

Towards novel paradigms for cancer therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20935674%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20935674%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Raoul Herbrecht

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20935674%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Hinrich Gronemeyer

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20935674%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

author name string

V Pavet

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20935674%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

J C Moulin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20935674%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

language of work or name

English

0 references

publication date

11 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20935674%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20935674%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20935674%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20935674%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

page(s)

1-20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20935674%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/onc.2010.460

15 February 2020

exact match

0 references

cites work

HAMLET (human alpha-lactalbumin made lethal to tumor cells) triggers autophagic tumor cell death

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Replicative adenoviruses for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Apoptin: therapeutic potential of an early sensor of carcinogenic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

DNA polymerases as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

PML regulates p53 stability by sequestering Mdm2 to the nucleolus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Rational bases for the development of EGFR inhibitors for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

High-throughput crystallography for lead discovery in drug design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

The imprinted H19 noncoding RNA is a primary microRNA precursor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Inhibition of endothelial cell apoptosis by netrin-1 during angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Adverse effects of anticancer agents that target the VEGF pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Non-coding RNAs, epigenetics and complexity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

PML is a direct p53 target that modulates p53 effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Integrins in cancer: biological implications and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Clinical development of histone deacetylase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

HAMLET interacts with histones and chromatin in tumor cell nuclei

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Loss of MDA-7 expression with progression of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

The let-7 microRNA reduces tumor growth in mouse models of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

21 January 2018

Epigenetics in cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

The history of cancer epigenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Hypomethylation distinguishes genes of some human cancers from their normal counterparts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Small-molecule pan-IAP antagonists: a patent review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Towards the human cancer epigenome: a first draft of histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Oncolytic virus therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Inhibitor of apoptosis proteins in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

A census of human cancer genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

The 5-methylcytosine content of DNA from human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Dependence receptors: a new paradigm in cell signaling and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Patterns of somatic mutation in human cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Targeting angiogenesis: progress with anti-VEGF treatment with large molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Identification of selective inhibitors of cancer stem cells by high-throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Changes in proteasome structure and function caused by HAMLET in tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Treatment of skin papillomas with topical alpha-lactalbumin-oleic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Apoptosis induced by a human milk protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Modulation of tumor necrosis factor apoptosis-inducing ligand- induced NF-kappa B activation by inhibition of apical caspases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Sensitivity of adult T-cell leukaemia lymphoma cells to tumour necrosis factor-related apoptosis-inducing ligand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Mechanisms of selective anticancer action of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Impairment of p53 acetylation, stability and function by an oncogenic transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Biomarkers of response and resistance to antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

New strategies in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Genomic DNA methylation: the mark and its mediators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Targeting the cancer kinome through polypharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Curing APL: differentiation or destruction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Protease activation in apoptosis induced by MAL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

BCL-2 family antagonists for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

The adenovirus E4orf4 protein induces G2/M arrest and cell death by blocking protein phosphatase 2A activity regulated by the B55 subunit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

The adenovirus E4orf4 protein induces growth arrest and mitotic catastrophe in H1299 human lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Cytoplasmic PML function in TGF-beta signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Role of the histone deacetylase complex in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Gene therapy progress and prospects cancer: oncolytic viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Principles of cancer therapy: oncogene and non-oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Cancer-selective therapy of the future: apoptin and its mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Netrin-1 and its dependence receptors as original targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Metastasis: a question of life or death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Bladder cancers respond to intravesical instillation of HAMLET (human alpha-lactalbumin made lethal to tumor cells).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Is TRAIL the holy grail of cancer therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Proteins selectively killing tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

NS1 interaction with CKII alpha: novel protein complex mediating parvovirus-induced cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

A viral adaptor protein modulating casein kinase II activity induces cytopathic effects in permissive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Inhibition of hepatocarcinoma by systemic delivery of Apoptin gene via the hepatic asialoglycoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

The non-coding RNA of the multidrug resistance-linked vault particle encodes multiple regulatory small RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Efficient tumour formation by single human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Illuminating the silence: understanding the structure and function of small RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

The viral death effector Apoptin reveals tumor-specific processes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Acquired and innate resistance to the cancer-specific apoptosis-inducing cytokine, mda-7/IL-24: not insurmountable therapeutic problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Identification of cells initiating human melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Growth factor-antagonized rexinoid apoptosis involves permissive PPARgamma/RXR heterodimers to activate the intrinsic death pathway by NO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Vitamin E succinate in combination with mda-7 results in enhanced human ovarian tumor cell killing through modulation of extrinsic and intrinsic apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Dynamic Regulation of Histone Lysine Methylation by Demethylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Molecular definition of breast tumor heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

The tumor suppressor activity of MDA-7/IL-24 is mediated by intracellular protein expression in NSCLC cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

PTD4-apoptin protein therapy inhibits tumor growth in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

HAMLET kills tumor cells by an apoptosis-like mechanism--cellular, molecular, and therapeutic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Programmed cell death pathways and current antitumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Targeting metabolic transformation for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Dependence receptors: mechanisms of an announced death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Switching from repression to activation: microRNAs can up-regulate translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

TRAIL induces proliferation of human glioma cells by c-FLIPL-mediated activation of ERK1/2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Interleukin-24 and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

The genomic landscapes of human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Histone deacetylase inhibitors: molecular mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Haploinsufficiency of Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Targeting cancer with small molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Mechanisms of resistance to TRAIL-induced apoptosis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Mechanisms of anti-cancer action and pharmacology of clofarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Tumour-initiating cells: challenges and opportunities for anticancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Ad-MDA-7; INGN 241: a review of preclinical and clinical experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Apoptosis and tumor cell death in response to HAMLET (human alpha-lactalbumin made lethal to tumor cells).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Viral proteins killing tumor cells: new weapons in the fight against cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Avoiding premature apoptosis of normal epidermal cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Acute myelogenous leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Acute promyelocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Growth factor receptor tyrosine kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Recruitment of RXR by Homotetrameric RARα Fusion Proteins Is Essential for Transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460

Cutting Edge: TRAIL Deficiency Accelerates Hematological Malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.460